Enveric Biosciences, Inc. (ENVB) Financials

ENVB Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2023 6.6 million 4.2 million
June 30, 2023 9.8 million 4.9 million
March 31, 2023 15.9 million 4.4 million
Dec. 31, 2022 19.6 million 4.0 million

ENVB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -2.7 million 372859
June 30, 2023 -4.5 million 879738
March 31, 2023 -5.1 million 532835
Dec. 31, 2022 -3.5 million 529372

ENVB Net Income

No data available :(

ENVB Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 4.3 million - -
June 30, 2023 7.1 million - 9611
March 31, 2023 12.6 million - 37044
Dec. 31, 2022 17.7 million - 63820

ENVB Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 2.2 million
June 30, 2023 2.1 million
March 31, 2023 2.1 million
Dec. 31, 2022 1.4 million

ENVB Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 8 1.4 million 2.0 million -
June 30, 2023 18 2.5 million 3.2 million -
March 31, 2023 5169 2.0 million 2.8 million -
Dec. 31, 2022 6193 1.9 million 2.8 million -

ENVB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - 95839
June 30, 2023 - 114374
March 31, 2023 - 113333
Dec. 31, 2022 - 90423

ENVB

Price: $1.36

52 week price:
1.25
17.64

Dividend Yield: 1009610.34%

Earnings Per Share: 1390.68 USD

P/E Ratio: -0.05

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 3818

Market Capitalization: 931339

Links: